New drug combo aims to shrink tough lung tumors
NCT ID NCT05904379
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests two experimental immunotherapy drugs, AK112 and AK104, given together with or without standard chemotherapy. The goal is to see if this combination can safely shrink tumors and control advanced non-small cell lung cancer. About 233 adults with stage IIIB/IV lung cancer who cannot have curative treatment are taking part.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
AK112 and AK104 (immunotherapy drugs), with or without chemotherapy (carboplatin, paclitaxel, pemetrexed, or docetaxel)
What this could lead to
If successful, this combination could offer a new treatment option that helps shrink tumors and control advanced lung cancer for longer.
What could go wrong
This is an early-phase trial (Phase 1/2) with a small number of participants, so results may not apply to all patients. Side effects from immunotherapy and chemotherapy can be serious.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Shanghai Pulmonary Hospital
Shanghai, China
-
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, China